ABSTRACT
Background@#Guselkumab is a monoclonal antibody that selectively targets interleukin-23 in the treatment of moderate to severe psoriasis. Several multinational clinical studies have reported on its efficacy. However, data on its efficacy and safety in Korean patients are currently very limited. @*Objective@#This study evaluated the real-world efficacy and safety of guselkumab for treating patients with moderate to severe psoriasis in Korea. @*Methods@#This single-center retrospective study included 40 patients treated with guselkumab for at least 12 weeks.Electronic medical records were reviewed for demographics, clinical characteristics, psoriasis area and severity index (PASI) score, body surface area, and adverse events. @*Results@#The average PASI score at baseline (12.0±8.3) was significantly reduced to 3.3±3.8 at week 12, 2.2±2.2 at week 36, and 1.6±1.5 at week 52. At week 60, 93%, 60%, and 33% of patients achieved a PASI of 75, 90, and 100, respectively. Obesity, psoriatic arthritis, and previous biologics treatment experience were not significant indicators of guselkumab treatment efficacy. Seven patients reported adverse events; however, none discontinued guselkumab treatment. @*Conclusion@#Guselkumab is an effective and safe treatment option for moderate to severe psoriasis in Korea.